Lek, a Sandoz company

Generic Pharmaceuticalslek.si

Company typePrivate
Founded-
Headquarters—
Headcount1,001–5,000
GTM typeB2B
OfferingHardware or Manufacturing

Lek, a Sandoz company firmographics

Firmographics

Name: Lek, a Sandoz company
Legal name: Lek d.d.
Website: https://lek.si
Company type: Private
Operating status: Operating
Headcount range: 1,001–5,000 employees
Ownership category
akta.pro rank

Lek, a Sandoz company industry classification

Industry

Product category: Generic Pharmaceuticals
NAICS: Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC: Pharmaceutical Preparations (2834)
akta.pro primary industry: Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
akta.pro secondary industries: Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

Keywords

Generic pharmaceuticals
Active pharmaceutical ingredients
Pharmaceutical manufacturing
Biopharmaceutical development
Finished dosage forms

Lek, a Sandoz company business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure

Lek, a Sandoz company product offering

Product offering

Core offering

Lek d.d. is a Slovenian pharmaceutical manufacturer operating as a member of the Sandoz group (a Novartis division). The company develops, produces, and supplies generic pharmaceutical products, active pharmaceutical ingredients (APIs), and finished dosage forms for the Slovenian market and the broader Sandoz global network. It serves as a key manufacturing and development hub within Sandoz's European operations.

Differentiator

Problem solved

Functional benefit

Companies that use Lek, a Sandoz company

Customer profile

Ideal customer profiles1 record

Lek, a Sandoz company technology and API

Technology

Technology focussed No

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Lek, a Sandoz company partnerships and signals

Strategic signal

Recent moves1 record

Lek, a Sandoz company competitors and assessment

Company assessment

Broad incumbents

Aurobindo Pharma: Indian-headquartered global generic pharmaceutical manufacturer; relevant as a comparator on cost-competitive generics production and EU market participation.
Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive small-molecule portfolio; a benchmark for scale, pricing pressure dynamics, and portfolio breadth relevant to Lek's market.
Sandoz: Parent company and global generics leader; comparable as the broader portfolio operator within which Lek sits, sharing generics focus and small-molecule production capabilities.
Viatris: Global generics and specialty pharmaceutical company formed via Mylan-Upjohn merger; a broad incumbent with overlapping generic portfolio and European manufacturing footprint.
Perrigo: US-headquartered generics and consumer self-care products company; a broad incumbent with comparable generics manufacturing model and European operations.

Emerging players

Alvotech: Icelandic-based biosimilars-focused pharmaceutical company; an emerging player in higher-value generics/biologics where Sandoz (and by extension Lek) is investing to move up the value chain.

Direct peers

Polpharma: Polish-based generic pharmaceutical manufacturer serving Central and Eastern Europe with similar product mix and EU regulatory positioning to Lek.
Krka: Slovenian-headquartered generic pharmaceutical manufacturer with comparable scale and product breadth; the most direct geographic and operational comparator to Lek within the Slovenian/CEE pharmaceutical landscape.
STADA Arzneimittel: European-headquartered generic and consumer health pharmaceutical company; directly comparable in business model, geographic focus, and generic small-molecule manufacturing profile.

Regional players

Gedeon Richter: Hungarian-headquartered pharmaceutical company with significant generics and originator business; comparable as a CEE European generics manufacturer of similar scale and orientation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights4 records

Customer concentration

Lek, a Sandoz company financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lek, a Sandoz company leadership team

Management profile

Number of profiles

Lek, a Sandoz company funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lek, a Sandoz company M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lek, a Sandoz company

What does Lek, a Sandoz company do?

Is Lek, a Sandoz company a public or private company?

Lek, a Sandoz company is a private company. It is classified as corporate owned and is currently operating.

When was Lek, a Sandoz company founded?

Lek, a Sandoz company was founded in -1. It employs 1,001 to 5,000 people.

Who are Lek, a Sandoz company's main competitors?

Broad incumbents on record are Aurobindo Pharma, Teva Pharmaceutical Industries, Sandoz, Viatris and Perrigo. Alvotech is listed as an emerging player. Direct peers are Polpharma, Krka and STADA Arzneimittel. Gedeon Richter is listed as a regional player.

Does Lek, a Sandoz company have an API?

No public API is recorded for Lek, a Sandoz company.

What industry is Lek, a Sandoz company in?

Lek, a Sandoz company's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC), with a secondary code of HLAGAHAG, Impurity / Reference Standard Synthesis & Characterization. Its NAICS code is 325412 and its SIC code is 2834.